RESUMO
The ongoing COVID-19 pandemic, declared by the World Health Organisation in March 2020, with the emergence of new, possibly more contagious and more virulent strains, remains a research subject, with the complex systemic involvement better described and understood, but also with a variety of skin and mucosal lesions described in the literature. Mucocutaneous lesions associated with SARS-CoV-2 infection are still under investigation, due to their polymorphic clinical aspect and incompletely understood pathogenic mechanism. The cutaneous inflammatory, exanthematous and purpuric rashes, erythemato-purpuric enanthems, oral ulcers, lichenoid oral lesions, conjunctivitis, conjunctival pseudomembranes, or corneal lesions have been described in patients with COVID-19. Several classifications have been proposed based on the clinical pattern, histological findings, and possible pathogenic mechanisms. The pathogenic mechanism, the diagnostic criteria, the prognostic importance of these lesions are still being debated. The diverse clinical aspects of dermatological manifestations render the diagnosis difficult. However, several clinical patterns strongly associated with COVID-19, such as chilblains, papulovesicular exanthems, and febrile rash require increased awareness and changes to the investigation protocols for these conditions, to include testing for SARS-CoV-2. In the present review, the mucocutaneous findings associated with the novel coronavirus infection, reported thus far in the literature, was provided.
RESUMO
Objective:To evaluate the Kyoto gastritis score for diagnosing Helicobacter pylori ( HP) infection in Chinese people. Methods:A total of 902 cases who underwent 13C-urea breath test and gastroscopy at the same time at the Digestive Endoscopy center of Renmin Hospital of Wuhan University from January 2020 to December 2020 were studied retrospectively, including 345 cases of HP-positive and 557 of HP-negative. The differences of mucosal features and Kyoto gastritis score between HP-positive and HP-negative patients were analyzed. A receiver operating characteristic curve was plotted to predict HP infection by Kyoto gastritis score. Results:Compared with HP-negative patients, nodules [8.1% (28/345) VS 0.2% (1/557), χ2=86.29, P<0.001], diffuse redness [47.8% (165/345) VS 6.6% (37/557), χ2=413.63, P<0.001], atrophy [27.8% (96/345) VS 13.8% (77/557), χ2=52.90, P<0.001] and fold enlargement [69.0% (238/345) VS 36.6% (204/557), χ2=175.38, P<0.001] occurred more frequently in HP-positive patients. For predicting HP infection, nodules showed the highest specificity [99.8% (556/557)] and positive predictive value [96.6% (28/29)], diffuse redness showed the largest area under the receiver operating characteristic curve (AUC) of 0.707, and fold enlargement showed the highest sensitivity [69.0% (238/345)] and negative predictive value [76.7% (353/460)]. The Kyoto gastritis score of HP-positive patients was higher than that of HP-negative patients [2 (1, 2) VS 0 (0, 1), Z=20.82, P<0.001]. Furthermore, at an optimal threshold of 2, the AUC of the Kyoto gastritis score for predicting HP infection was 0.779. Conclusion:Nodules, diffuse redness, atrophy and fold enlargement under gastroscopy can suggest positive of HP infection, and the Kyoto gastritis score≥2 is sufficient reference to diagnose HP positive.
